Intrathecal Midazolam, Fentanyl and Nalbuphine as Adjuvants to Bupivacaine in Spinal Anesthesia for Cesarean Section

• Status: Recruiting
• Trial end date: 2021-12-15
• Target enrollment: 0
• Participant gender: Female

Summary

The main limitations of spinal anesthesia are its short duration of action and do not provide prolonged postoperative analgesia when it is performed only with local anesthetics. Adding adjuvants drugs to intrathecal local anesthetics improves quality and duration of spinal blockade, and prolongs postoperative analgesia. It is also possible to reduce dose of local anesthetics, as well as total amount of systemic postoperative analgesics.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Benha University
• Treatments: Bupivacaine; Fentanyl; Midazolam; Nalbuphine

Criteria

Inclusion Criteria:

1. ASA physical status I and ASA II

2. Age from 18-40 years

3. Scheduled to undergo elective cesarean section under spinal anesthesia.

Exclusion Criteria:

1. ASA physical status III or IV patients.

2. Patients refuse spinal anesthesia.

3. Patients physically dependent on narcotics or benzodiazepine.

4. Patients with history of drug allergy to one of used adjuvants.

5. Patients with gross spinal abnormality, localized skin sepsis, hemorrhagic diathesis or neurological involvement/ diseases and any contraindication for spine.

6. Patients who are unable to communicate.

7. Morbid obesity.

8. Failure of spinal blockade.

9. Complicated pregnancy.